Insulin glulisine is a rapid-acting modified form of medical insulin that differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid.[4] It was developed by Sanofi-Aventis and approved for marketing by the FDA in 2004;[5] it is sold under the trade name Apidra.[6] When injected subcutaneously, it appears in the blood earlier than human insulin.[7] When used as a meal time insulin, the dose is to be administered within 15 minutes before or 20 minutes after starting a meal.[8] Intravenous injections may also be used for extreme hyperglycemia, but must be performed under the supervision of a medical professional.[2]
^Garnock-Jones KP, Plosker GL (May 2009). "Insulin glulisine: a review of its use in the management of diabetes mellitus". Drugs. 69 (8): 1035–57. doi:10.2165/00003495-200969080-00006. PMID 19496630. S2CID 41839395.
insulin, glulisine, rapid, acting, modified, form, medical, insulin, that, differs, from, human, insulin, that, amino, acid, asparagine, position, replaced, lysine, lysine, position, replaced, glutamic, acid, developed, sanofi, aventis, approved, marketing, 20. Insulin glulisine is a rapid acting modified form of medical insulin that differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid 4 It was developed by Sanofi Aventis and approved for marketing by the FDA in 2004 5 it is sold under the trade name Apidra 6 When injected subcutaneously it appears in the blood earlier than human insulin 7 When used as a meal time insulin the dose is to be administered within 15 minutes before or 20 minutes after starting a meal 8 Intravenous injections may also be used for extreme hyperglycemia but must be performed under the supervision of a medical professional 2 Insulin glulisinePDB 6gv0 Clinical dataTrade namesApidra Apidra SoloStarAHFS Drugs comMonographMedlinePlusa607033License dataEU EMA by INN US DailyMed Insulin glulisinePregnancycategoryAU B3 1 Routes ofadministrationSubcutaneous intravenousATC codeA10AB06 WHO Legal statusLegal statusAU S4 Prescription only UK POM Prescription only US only 2 EU Rx only 3 IdentifiersCAS Number207748 29 6 NDrugBankDB01309 YChemSpidernoneUNII7XIY785AZDKEGGD04540 YChemical and physical dataFormulaC 258H 384N 64O 78S 6Molar mass5822 64 g mol 1 N Y what is this verify The most common side effects include hypoglycaemia low blood glucose levels 3 Medical uses EditInsulin glulisine is indicated for the treatment of diabetes mellitus 3 2 References Edit a b Insulin glulisine Use During Pregnancy Drugs com 6 April 2020 Retrieved 21 September 2020 a b c Apidra insulin glulisine injection solution Apidra SoloStar insulin glulisine injection solution DailyMed 6 December 2019 Retrieved 21 September 2020 a b c Apidra EPAR European Medicines Agency EMA Retrieved 7 October 2020 Apidra insulin glulisine injection solution DailyMed Apidra FDA Approval History Drugs com Retrieved 25 August 2022 Jasek W ed 2007 Austria Codex in German 2007 2008 ed Vienna Osterreichischer Apothekerverlag ISBN 978 3 85200 181 4 Garnock Jones KP Plosker GL May 2009 Insulin glulisine a review of its use in the management of diabetes mellitus Drugs 69 8 1035 57 doi 10 2165 00003495 200969080 00006 PMID 19496630 S2CID 41839395 Insulin Glulisine Drugs com External links Edit Insulin glulisine Drug Information Portal U S National Library of Medicine Portal Medicine This drug article relating to the gastrointestinal system is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Insulin glulisine amp oldid 1106619883, wikipedia, wiki, book, books, library,
